June 20, 2017 <\/p>\n
Improvement in nail psoriasis severity at 16 weeks vs placebo; maintained through 52 weeks <\/p>\n
HealthDay News Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the July issue of the Journal of the American Academy of Dermatology. <\/p>\n
Joseph F. Merola, MD, from Brigham and Women's Hospital in Boston, and colleagues examined the efficacy of tofacitinib for nail psoriasis treatment over 52 weeks in two identical phase 3 studies. Patients were randomized to receive tofacitinib 5 mg (487 patients), tofacitinib 10 mg (476 patients), or placebo (233 patients) twice daily. Placebo-treated patients were re-randomized at week 16. <\/p>\n
The researchers found that significantly more patients receiving tofacitinib 5mg and tofacitinib 10mg versus placebo achieved a 50% reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50) (32.8 and 44.2, respectively, versus 12.0 percent), NAPSI75 (16.9 and 28.1, respectively, versus 6.8 percent), and NAPSI100 (10.3 and 18.2, respectively, versus 5.1 percent) at week 16. The improvements were maintained to week 52. <\/p>\n
\"Tofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks,\" the authors write. <\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Pfizer, which manufactures tofacitinib and funded the study. <\/p>\n
Abstract Full Text <\/p>\n
<\/p>\n
See the original post here: June 20, 2017 Improvement in nail psoriasis severity at 16 weeks vs placebo; maintained through 52 weeks HealthDay News Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the July issue of the Journal of the American Academy of Dermatology. Continue reading
\nTofacitinib Assessed for Efficacy in Nail Psoriasis - Monthly Prescribing Reference (registration)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"